Septerna to Participate in Upcoming Investor Conferences

Core Insights - Septerna, Inc. is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery [1][2] - The company will participate in two upcoming investor conferences in September 2025, showcasing its commitment to engaging with investors [1] Company Overview - Septerna is advancing GPCR therapies to address significant unmet medical needs, utilizing its proprietary Native Complex Platform™ for drug discovery [2] - The company has developed a diverse pipeline of novel oral small molecule drug candidates across various therapeutic areas, including endocrinology, immunology, inflammation, and metabolic diseases [2]